Neurocrine Biosciences Seeks $250M In Public Offering
Biopharmaceutical company Neurocrine Biosciences Inc. said Thursday that it hopes to raise about $250 million via public offering of almost 7 million shares, the proceeds of which will go toward research...To view the full article, register now.
Already a subscriber? Click here to view full article